Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
Published: Mar 16, 2009
Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio
NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small molecule that selectively inhibits the activation of all three isoforms of Akt. Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation, survival and invasiveness
Co-inventors are Jin Q. Cheng, M.D., Ph.D. and Said M. Sebti, Ph.D. from Moffitt. "This small molecule is a highly selective and potent inhibitor of Akt activation, leading to tumor growth arrest and induction of cancer cell death, and results in overcoming chemoresistance," said Dr. Cheng, Professor, Molecular Oncology Department at Moffitt. "Patients whose tumors contain persistently activated Akt are predicted to be more likely to respond to this inhibitor either as a single agent or in combination therapy," said Dr Sebti, Professor and Chair, Drug Discovery Department at Moffitt. "Akt is abnormally hyperactivated in many advanced malignancies and late stage tumors, such as breast, prostate, lung, pancreatic, liver, ovarian and colorectal cancers. Increased activation is also linked with drug and radiation resistance," said Dr. Cheng.
Through this license, Lyndor plans to develop and commercialize the new anti-cancer agent, which it refers to as LD-101, for refractory and resistant tumors as well as metastatic malignancies, addressing a huge unmet medical need. "Given time, most cancers will relapse, become resistant and, ultimately, refractory. In fact, most become metastatic before detection," said Susan Rosenbaum, Esq., Chairman and CEO of Samtheo. "Lyndor's agreement with Moffitt will enable Lyndor to develop this targeted therapeutic for personalized medicine in the treatment of patients with these difficult-to-treat diseases." Under the license agreement, Lyndor has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed products.
About H. Lee Moffitt Cancer Center & Research Institute
Located in Tampa, Florida, Moffitt Cancer Center (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control.
Lyndor is a privately-held subsidiary of Samtheo that acquired the exclusive, world-wide rights to its lead compound, LD-101, from Moffitt. Lyndor's interest in the treatment of cancer and development of LD-101 as an effective targeted therapeutic agent for personalized medicine is propelled by the desire to improve cancer treatment, offer patients greater life expectancy and provide a better quality of life.
Samtheo is a privately-held company that invests in biotechnology companies focused on the delivery of personalized medicine through targeted therapeutics. Samtheo is in the business of acquisition, development and commercialization of innovative technology "with integrity", i.e., proprietary, novel intellectual property that will generate evidence-based, medically-effective and socially-assessable products. Samtheo's global mission is to improve health care and outcomes dramatically for patients with life-threatening diseases and unmet medical needs. Samtheo's press releases and other company information are available at www.samtheo.com.
CONTACT: Michelle Foley of Moffitt Cancer Center, +1-813-745-1505; or
Susan Rosenbaum, Esq. of Samtheo Biopharma LLC, +1-347-497-2446
Web site: http://www.samtheo.com/